Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3033 - 3040 of 12086 results
EXCLUSIVE RIGHTS: Intellectual Property — A Patent Damages Deep Dive with Mintz and BDO — Part I of II
July 22, 2021| Podcast| Viewpoint
Are You a Medical Device Servicer or Remanufacturer? FDA’s New Guidance May Help…Or Not
July 21, 2021| Blog| Viewpoint
Biden Administration Takes Aim at Rising Drug Prices through its Executive Order on Promoting Competition
July 20, 2021| Blog| Viewpoint
California AG Releases Important CCPA Enforcement Information and Announces an Online Consumer Reporting Tool
July 20, 2021| Blog| Viewpoint
How Western States Help The Wealthy Avoid Taxes, Creditors
July 19, 2021| News
Energy & Sustainability Connections Newsletter – July 2021
July 19, 2021| Article| Viewpoint
Energy & Sustainability Client Feature: AeroShield Wins Department of Energy American-made Solar Prize
July 19, 2021| Article| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|